Financial Survey: Zenas BioPharma (NASDAQ:ZBIO) vs. Chemomab Therapeutics (NASDAQ:CMMB)

Chemomab Therapeutics (NASDAQ:CMMB) and Zenas BioPharma (NASDAQ:ZBIO) are both small-cap medical companies, but which is the better business? We will contrast the two businesses based on the strength of their dividends, analyst recommendations, risk, institutional ownership, earnings, valuation and profitability.

Earnings & Valuation

This table compares Chemomab Therapeutics and Zenas BioPharma”s revenue, earnings per share and valuation.

	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Chemomab Therapeutics	N/A	N/A	-$13.94 million	($2.96)	-0.57
Zenas BioPharma	$5.00 million	215.69	-$156.99 million	($7.07)	-2.84

Chemomab Therapeutics has higher earnings, but lower revenue than Zenas BioPharma. Zenas BioPharma is trading at a lower price-to-earnings ratio than Chemomab Therapeutics, indicating that it is currently the more affordable of the two stocks.

Profitability

This table compares Chemomab Therapeutics and Zenas BioPharma’s net margins, return on equity and return on assets.

	Net Margins	Return on Equity	Return on Assets
Chemomab Therapeutics	N/A	-110.78%	-93.27%
Zenas BioPharma	N/A	-73.55%	-57.60%

Institutional and Insider Ownership

46.1% of Chemomab Therapeutics shares are held by institutional investors. 11.9% of Chemomab Therapeutics shares are held by insiders. Comparatively, 16.5% of Zenas BioPharma shares are held by insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a company will outperform the market over the long term.

Volatility and Risk

Chemomab Therapeutics has a beta of 0.51, meaning that its stock price is 49% less volatile than the S&P 500. Comparatively, Zenas BioPharma has a beta of -1.45, meaning that its stock price is 245% less volatile than the S&P 500.

Analyst Ratings

This is a summary of recent recommendations for Chemomab Therapeutics and Zenas BioPharma, as reported by MarketBeat.com.

	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Chemomab Therapeutics	1	1	2	0	2.25
Zenas BioPharma	1	1	6	0	2.63

Chemomab Therapeutics currently has a consensus target price of $26.50, suggesting a potential upside of 1,477.38%. Zenas BioPharma has a consensus target price of $43.14, suggesting a potential upside of 114.75%. Given Chemomab Therapeutics’ higher probable upside, equities analysts plainly believe Chemomab Therapeutics is more favorable than Zenas BioPharma.

About Chemomab Therapeutics

Chemomab Therapeutics Ltd., a clinical-stage biotechnology company, discovers and develops therapeutics for the treatment of fibrotic and inflammatory diseases. The company's lead clinical product candidate is CM-101, a humanized monoclonal antibody had completed Phase 2a clinical trials that hinders the basic function of soluble chemokine CCL24 for the treatment of primary sclerosing cholangitis (PSC) and systemic sclerosis (SSc). The company was formerly known as Anchiano Therapeutics Ltd. and changed its name to Chemomab Therapeutics Ltd. in March 2021. Chemomab Therapeutics Ltd. was founded in 2011 and is based in Tel Aviv, Israel.

About Zenas BioPharma

Zenas BioPharma, Inc. is a clinical-stage global biopharmaceutical company, which engages in the development and commercialization of transformative immunology-based therapies for patients. The company was founded by Lonnie O. Moulder Jr on November 12, 2019 and is headquartered in Waltham, MA.